Abilify Patent Expiration sends BMS 2015 top line forecast south.

Obviously the street was anticipating the May 2015 expiration of the Abilify patent and for low cost generics to step in; thusly, the shares stay intact.

SMZ

https://mail.google.com/mail/u/0/#inbox/14b2c84151615a97